Humacyte
HUMAHumacyte is a commercial-stage biotechnology company that pioneers the development and large-scale manufacture of off-the-shelf, universally implantable, bioengineered human tissues.
Table of contents
Earnings
Next report
Aug 10, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Humacyte is a commercial-stage biotechnology company that pioneers the development and large-scale manufacture of off-the-shelf, universally implantable, bioengineered human tissues. The company's proprietary platform creates acellular tissue engineered vessels (ATEVs) designed to repair, reconstruct, and replace human tissue without inducing immune rejection. Their core value proposition lies in providing a ready-to-use regenerative medicine alternative to autologous vein grafts and synthetic materials.
Humacyte is a first-mover in the bioengineered acellular tissue space with the first FDA-approved ATEV and multiple RMAT designations.
Questions, answered.
- What is Humacyte's market cap?
- Humacyte (HUMA) has a market capitalization of $181.8M and trades on NASDAQ.
- Who are Humacyte's competitors?
- Humacyte's key competitors include Artivion, LeMaitre Vascular, Baxter International, and others. These companies compete in similar markets and product categories.
- Who does Humacyte partner with?
- Humacyte's notable partners include U.S. Department of Defense, U.S. Food and Drug Administration.
- What subsidiaries does Humacyte have?
- Humacyte's subsidiaries include Humacyte Global, Inc..
- Where is Humacyte headquartered?
- Humacyte is headquartered in United States of America and employs approximately 185 people. It has been publicly traded since 2021.